CD4+ T cell expression of the IL-10 receptor is necessary for facial motoneuron survival after axotomy.
Animals
Axotomy
/ methods
CD4-Positive T-Lymphocytes
/ metabolism
Cell Survival
/ physiology
Cells, Cultured
Facial Nerve
/ metabolism
Facial Nerve Injuries
/ genetics
Female
Gene Expression
Mice
Mice, 129 Strain
Mice, Inbred C57BL
Mice, Knockout
Mice, Transgenic
Motor Neurons
/ metabolism
Receptors, Interleukin-10
/ biosynthesis
Autoimmune
Axotomy
IL-10
Motoneuron
Nerve injury
Neuroprotection
T cell
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
17 Apr 2020
17 Apr 2020
Historique:
received:
07
11
2019
accepted:
16
03
2020
entrez:
19
4
2020
pubmed:
19
4
2020
medline:
29
1
2021
Statut:
epublish
Résumé
After peripheral nerve transection, facial motoneuron (FMN) survival depends on an intact CD4+ T cell population and a central source of interleukin-10 (IL-10). However, it has not been determined previously whether CD4+ T cells participate in the central neuroprotective IL-10 cascade after facial nerve axotomy (FNA). Immunohistochemical labeling of CD4+ T cells, pontine vasculature, and central microglia was used to determine whether CD4+ T cells cross the blood-brain barrier and enter the facial motor nucleus (FMNuc) after FNA. The importance of IL-10 signaling in CD4+ T cells was assessed by performing adoptive transfer of IL-10 receptor beta (IL-10RB)-deficient CD4+ T cells into immunodeficient mice prior to injury. Histology and qPCR were utilized to determine the impact of IL-10RB-deficient T cells on FMN survival and central gene expression after FNA. Flow cytometry was used to determine whether IL-10 signaling in T cells was necessary for their differentiation into neuroprotective subsets. CD4+ T cells were capable of crossing the blood-brain barrier and associating with reactive microglial nodules in the axotomized FMNuc. Full induction of central IL-10R gene expression after FNA was dependent on CD4+ T cells, regardless of their own IL-10R signaling capability. Surprisingly, CD4+ T cells lacking IL-10RB were incapable of mediating neuroprotection after axotomy and promoted increased central expression of genes associated with microglial activation, antigen presentation, T cell co-stimulation, and complement deposition. There was reduced differentiation of IL-10RB-deficient CD4+ T cells into regulatory CD4+ T cells in vitro. These findings support the interdependence of IL-10- and CD4+ T cell-mediated mechanisms of neuroprotection after axotomy. CD4+ T cells may potentiate central responsiveness to IL-10, while IL-10 signaling within CD4+ T cells is necessary for their ability to rescue axotomized motoneuron survival. We propose that loss of IL-10 signaling in CD4+ T cells promotes non-neuroprotective autoimmunity after FNA.
Sections du résumé
BACKGROUND
BACKGROUND
After peripheral nerve transection, facial motoneuron (FMN) survival depends on an intact CD4+ T cell population and a central source of interleukin-10 (IL-10). However, it has not been determined previously whether CD4+ T cells participate in the central neuroprotective IL-10 cascade after facial nerve axotomy (FNA).
METHODS
METHODS
Immunohistochemical labeling of CD4+ T cells, pontine vasculature, and central microglia was used to determine whether CD4+ T cells cross the blood-brain barrier and enter the facial motor nucleus (FMNuc) after FNA. The importance of IL-10 signaling in CD4+ T cells was assessed by performing adoptive transfer of IL-10 receptor beta (IL-10RB)-deficient CD4+ T cells into immunodeficient mice prior to injury. Histology and qPCR were utilized to determine the impact of IL-10RB-deficient T cells on FMN survival and central gene expression after FNA. Flow cytometry was used to determine whether IL-10 signaling in T cells was necessary for their differentiation into neuroprotective subsets.
RESULTS
RESULTS
CD4+ T cells were capable of crossing the blood-brain barrier and associating with reactive microglial nodules in the axotomized FMNuc. Full induction of central IL-10R gene expression after FNA was dependent on CD4+ T cells, regardless of their own IL-10R signaling capability. Surprisingly, CD4+ T cells lacking IL-10RB were incapable of mediating neuroprotection after axotomy and promoted increased central expression of genes associated with microglial activation, antigen presentation, T cell co-stimulation, and complement deposition. There was reduced differentiation of IL-10RB-deficient CD4+ T cells into regulatory CD4+ T cells in vitro.
CONCLUSIONS
CONCLUSIONS
These findings support the interdependence of IL-10- and CD4+ T cell-mediated mechanisms of neuroprotection after axotomy. CD4+ T cells may potentiate central responsiveness to IL-10, while IL-10 signaling within CD4+ T cells is necessary for their ability to rescue axotomized motoneuron survival. We propose that loss of IL-10 signaling in CD4+ T cells promotes non-neuroprotective autoimmunity after FNA.
Identifiants
pubmed: 32303238
doi: 10.1186/s12974-020-01772-x
pii: 10.1186/s12974-020-01772-x
pmc: PMC7164177
doi:
Substances chimiques
Receptors, Interleukin-10
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
121Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM077229
Pays : United States
Organisme : NINDS NIH HHS
ID : NS40433
Pays : United States
Références
Eur J Immunol. 1999 Feb;29(2):686-92
pubmed: 10064086
Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20960-5
pubmed: 19933335
Neurobiol Dis. 2011 Jun;42(3):211-20
pubmed: 21220013
Am J Pathol. 1992 Mar;140(3):691-707
pubmed: 1347673
FASEB J. 2000 Sep;14(12):1666-8
pubmed: 10973911
J Neurosci. 1999 Jun 1;19(11):RC7
pubmed: 10341268
Brain Behav Immun. 2010 May;24(4):641-51
pubmed: 20138983
PLoS One. 2013;8(3):e59647
pubmed: 23527240
Exp Neurol. 2006 Sep;201(1):212-24
pubmed: 16806176
J Neurochem. 2009 Sep;110(5):1617-27
pubmed: 19575707
J Neuropathol Exp Neurol. 1995 Mar;54(2):175-87
pubmed: 7533208
Exp Neurol. 2009 Nov;220(1):183-90
pubmed: 19716366
Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17843-8
pubmed: 15591351
J Neurodegener Regen. 2009 Sep 1;2(1):39-44
pubmed: 20436785
ASN Neuro. 2009 Dec 11;1(5):e00024
pubmed: 19922414
Neurosci Lett. 2012 Sep 27;526(2):138-43
pubmed: 22922129
Brain Behav Immun. 2011 Jul;25(5):820-9
pubmed: 20723599
Eur J Immunol. 2000 Jun;30(6):1683-90
pubmed: 10898505
Cytokine Growth Factor Rev. 2010 Oct;21(5):325-30
pubmed: 20846897
Eur J Immunol. 2008 Feb;38(2):576-86
pubmed: 18200504
J Comp Neurol. 2004 Mar 15;470(4):382-99
pubmed: 14961564
J Exp Med. 2011 May 9;208(5):1027-40
pubmed: 21518800
J Neurosci Res. 1988 Sep;21(1):18-24
pubmed: 3216409
Glia. 2015 Jul;63(7):1166-84
pubmed: 25691003
Science. 2016 May 6;352(6286):712-716
pubmed: 27033548
J Exp Med. 1998 Feb 16;187(4):571-8
pubmed: 9463407
J Comp Neurol. 2014 Jul 1;522(10):2349-76
pubmed: 24424947
Exp Neurol. 2007 Nov;208(1):92-9
pubmed: 17761165
Brain Behav Immun. 2003 Oct;17(5):393-402
pubmed: 12946661
J Immunol. 1994 May 1;152(9):4368-74
pubmed: 7512591
J Immunol. 1997 Nov 15;159(10):4772-80
pubmed: 9366401
J Immunol. 2006 Feb 1;176(3):1402-10
pubmed: 16424167
Cell Physiol Biochem. 2017;44(1):357-367
pubmed: 29132135
J Neurosci. 1998 Aug 1;18(15):5804-16
pubmed: 9671668
J Exp Med. 1996 Nov 1;184(5):1737-45
pubmed: 8920862
J Immunol. 2000 Aug 1;165(3):1175-81
pubmed: 10903714
J Neuroimmunol. 2006 Jul;176(1-2):34-8
pubmed: 16766044
J Neuroimmunol. 1998 Nov 2;91(1-2):180-9
pubmed: 9846834
Brain Behav Immun. 2018 Feb;68:98-110
pubmed: 29030217
EMBO J. 1997 Oct 1;16(19):5894-903
pubmed: 9312047
Brain Behav Immun. 2011 Jan;25(1):77-82
pubmed: 20727964
J Neurosci. 2016 Oct 26;36(43):11074-11083
pubmed: 27798187
Brain Res Mol Brain Res. 2000 Mar 29;76(2):429-35
pubmed: 10762723
J Neuroimmunol. 2009 Apr 30;209(1-2):65-80
pubmed: 19246105
J Neuroimmunol. 1989 Feb;21(2-3):117-23
pubmed: 2913044
Exp Transl Stroke Med. 2013 Nov 13;5(1):12
pubmed: 24499655
J Orthop Rheumatol. 2013 Nov 1;1(1):4
pubmed: 25309946
Clin Exp Immunol. 2011 Aug;165(2):163-71
pubmed: 21635228
Immunol Cell Biol. 2009 Mar-Apr;87(3):235-40
pubmed: 19104504
J Neuroinflammation. 2016 Nov 24;13(1):297
pubmed: 27881137
J Neuroimmunol. 2003 Jan;134(1-2):95-103
pubmed: 12507776
J Neurosci. 2004 May 5;24(18):4333-9
pubmed: 15128847
J Neurol Sci. 1987 Aug;80(1):25-37
pubmed: 3302117
Trends Cogn Sci. 2017 Oct;21(10):760-778
pubmed: 28754595
Glia. 2014 May;62(5):804-17
pubmed: 24677019
Acta Neuropathol. 1971;17(3):265-82
pubmed: 5552043
Brain Behav Immun. 2015 Mar;45:157-70
pubmed: 25476600
Immunity. 2009 May;30(5):646-55
pubmed: 19464987
Cell. 1994 Jan 28;76(2):275-85
pubmed: 7904901
Synapse. 2008 Feb;62(2):137-48
pubmed: 18000810
Inflamm Bowel Dis. 2017 Nov;23(11):1950-1961
pubmed: 29023267
J Neurosci Res. 2000 Oct 15;62(2):273-8
pubmed: 11020219
Immunology. 2006 Apr;117(4):433-42
pubmed: 16556256
Brain Res. 1990 Jul 23;523(2):273-80
pubmed: 2400911
Eur J Neurosci. 2007 Apr;25(7):2053-64
pubmed: 17439492
J Neurosci. 2004 Apr 14;24(15):3752-61
pubmed: 15084655
Neurosci Lett. 1988 Mar 10;85(3):317-21
pubmed: 3362421
Brain Res. 1997 Sep 26;769(2):391-5
pubmed: 9374212
J Neuroimmunol. 2009 Nov 30;216(1-2):66-75
pubmed: 19818514
Immunology. 2001 Jun;103(2):131-6
pubmed: 11412299
J Vis Exp. 2015 Feb 23;(96):e52382
pubmed: 25742324
J Biol Chem. 2002 Oct 18;277(42):39327-33
pubmed: 12176974
Neuron. 2012 May 24;74(4):691-705
pubmed: 22632727
J Immunol. 2014 Mar 1;192(5):2339-48
pubmed: 24489093
Sci Rep. 2016 Jul 26;6:30459
pubmed: 27456198
J Neuroimmunol. 2011 Jun;235(1-2):104-9
pubmed: 21501881